Clofexamide (or Amichlophene) is an antidepressant that was a component of the drug combination clofezone, the other being the nonsteroidal anti-inflammatory drug (NSAID) phenylbutazone. Clofezone potentiated hexobarbital-induced sleep in mice, prevented tolerance to morphine, increased uterine motility in rabbits, inhibited Pentetrazole seizure and toxic effects of bacterial polysaccharides in mice, inhibited the action potential of rat sciatic nerves, but had no significant effect on blood pressure, heart function, blood coagulation, hemolysis, respiration, or intestinal motility in rabbits. Clofezone was used to treat joint and muscular pain but is not marketed anymore.

Watanidipine (AE0047) had been NDA filed for the treatment of hypertension in Japan. Watanidipine (as Calbren®) was awaiting registration with Mitsubishi Pharma Corporation in Japan. However, Mitsubishi Pharma Corporation has discontinued the development of this drug. Watanidipine had also been in phase II clinical trials for the treatment of stroke and preclinical trials for atherosclerosis. However, no recent development has been reported. Watanidipine (AE0047) has being shown to be a calcium antagonist with protective effects against cerebral ischaemia and the occurrence of stroke in several animal models.

Enilconazole is a synthetic broad-spectrum antimycotic with a high activity against most of the common dermatophytes and various other fungi and yeasts. It is a selective inhibitor of ergosterol biosynthesis, an essential component of the cell membrane of fungi and yeasts. This results in irreversible changes which are the origin of the fungicidal effect. Enilconazole is marketed under the brand name Imaverol among others. Imaverol concentrated solution is a synthetic antimycotic with a potent antifungal action against dermatophytes such as: Trichophyton verrucosum, Trichophyton mentagrophytes, Trichophyton equinum, and Microsporum canis in horses and dogs.

Ethybenzatropine (Ponalid) is an anticholinergic and antihistaminergic drug. It was used as an antiparkinsonian agent. A significant increase in the duration of action of levodopa-induced improvement in parkinsonian symptoms was observed following the administration of ethybenzatropine. Ethybenzatropine also improved, or tended to improve the duration and seventy of onset and end-of-dose levodopa-induced dyskinesias. Thus when levodopa is administered together with etybenzatropine, its length of action on parkinsonian symptoms is prolonged.

Pipethanate ethobromide is an antimuscarinic with actions similar to those of atropine. It has been used in the symptomatic treatment of visceral spasms in oral doses of up to 160 mg daily in divided doses. Pipethanate ethobromide has also been given intramuscularly or intravenously in doses of 10 to 20 mg daily and rectally in doses of 60 or 120 mg daily.

Oral dehydroemetine dihydrochloride (+/-) (Mebadin) was found useful both as a tissue and contact amoebicide. It is much less toxic and more active than emetine and can be given in larger doses and for longer periods with safety. Owing to the quick excretion, repeat courses can be given at short intervals, as necessary, without danger. No serious side effects were noted particularly with the oral form and it was far better tolerated by children, who received relatively higher dosage than most adults. The only contra-indication is for patients with manifest decompensation of vital organs, or fevers. Mebadin injection and Mebadin tablets are discontinued products.

TZC-5665 (Oberadilol) is a pyridazinone derivative with vasodilatory and beta-adrenergic blocking activities and type III phosphodiesterase inhibitory action

Antihistamine agent

Acotiamide (Acofide(®)), an oral first-in-class prokinetic drug, is under global development by Zeria Pharmaceutical Co. Ltd and Astellas Pharma Inc. for the treatment of patients with functional dyspepsia. The drug modulates upper gastrointestinal motility to alleviate abdominal symptoms resulting from hypomotility and delayed gastric emptying. It exerts its activity in the stomach via muscarinic receptor inhibition, resulting in enhanced acetylcholine release and inhibition of acetylcholinesterase activity. Acofide® is launched in Japan for treating functional dyspepsia.

Prenoxdiazine under the brand name Libexin is used as an antitussive agent. It was shown, that the use of this drug for pregnant women with an unproductive cough could be beneficial.